Literature DB >> 18711212

Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody.

Persefoni Klimentzou1, Angeliki Drougou, Birgit Fehrenbacher, Martin Schaller, Wolfgang Voelter, Calypso Barbatis, Maria Paravatou-Petsotas, Evangelia Livaniou.   

Abstract

Prothymosin alpha (ProTalpha) is a nuclear polypeptide of great biological and, possibly clinical, importance, because its expression levels have been associated with early diagnosis/prognosis of human cancer. It is therefore interesting to raise easily available and cost-effective antibodies that would be applied to develop reliable ProTalpha immunodiagnostics. In this study, New Zealand white rabbits and laying hens were parallel immunized against intact ProTalpha or the synthetic fragments ProTalpha[1-28], ProTalpha[87-109], and ProTalpha[101-109], all conjugated to keyhole limpet hemocyanin (KLH). The corresponding antibodies G and Y were immunochemically evaluated in parallel with ELISA and Western blot systems and applied to fluorescence immunocytology experiments using various cancer cell lines and normal cells. The antibody G raised against ProTalpha[101-109]/KLH had excellent functional characteristics in the Western blot and immunocytology experiments, where the fluorescent signal was almost exclusively shown in the cell nucleus independently of the cells assayed. The above antibody has been applied to preliminary IHC staining of human cancer prostate tissues, leading to a high percentage of clearly and intensively stained nuclei in the adenocarcinoma tissue; this antibody can be further used in cancer tissue immunostaining and in research concerning the role of ProTalpha in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18711212      PMCID: PMC2569898          DOI: 10.1369/jhc.2008.950956

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  38 in total

1.  Functional discontinuities in prothymosin alpha caused by caspase cleavage in apoptotic cells.

Authors:  S A Enkemann; R H Wang; M W Trumbore; S L Berger
Journal:  J Cell Physiol       Date:  2000-02       Impact factor: 6.384

2.  Sensing prothymosin alpha origin, mutations and conformation with monoclonal antibodies.

Authors:  Elena A Sukhacheva; Alexandra G Evstafieva; Tatyana V Fateeva; Vitaliy R Shakulov; Nadezda A Efimova; Ruben N Karapetian; Yuri P Rubtsov; Andrey B Vartapetian
Journal:  J Immunol Methods       Date:  2002-08-01       Impact factor: 2.303

3.  Significance of plasma thymosin alpha1 measurements in gastric cancer patients.

Authors:  M Mitani; Y Kuwabara; H Kawamura; A Sato; K Hattori; Y Fujii
Journal:  World J Surg       Date:  2000-04       Impact factor: 3.352

4.  Mobility within the nucleus and neighboring cytosol is a key feature of prothymosin-alpha.

Authors:  S A Enkemann; R D Ward; S L Berger
Journal:  J Histochem Cytochem       Date:  2000-10       Impact factor: 2.479

Review 5.  Chicken antibodies: a clinical chemistry perspective.

Authors:  D Carlander; J Stålberg; A Larsson
Journal:  Ups J Med Sci       Date:  1999       Impact factor: 2.384

Review 6.  Generation and application of chicken egg-yolk antibodies.

Authors:  M Tini; U R Jewell; G Camenisch; D Chilov; M Gassmann
Journal:  Comp Biochem Physiol A Mol Integr Physiol       Date:  2002-03       Impact factor: 2.320

7.  Expression of prothymosin alpha is correlated with development and progression in human prostate cancers.

Authors:  Shugo Suzuki; Satoru Takahashi; Seishiro Takahashi; Kentaro Takeshita; Atsuya Hikosaka; Toshiaki Wakita; Naoki Nishiyama; Tamio Fujita; Takehiko Okamura; Tomoyuki Shirai
Journal:  Prostate       Date:  2006-04-01       Impact factor: 4.104

8.  Prothymosin alpha is processed to thymosin alpha 1 and thymosin alpha 11 by a lysosomal asparaginyl endopeptidase.

Authors:  Concepción S Sarandeses; Guillermo Covelo; Cristina Díaz-Jullien; Manuel Freire
Journal:  J Biol Chem       Date:  2003-01-28       Impact factor: 5.157

9.  Distinctive roles of PHAP proteins and prothymosin-alpha in a death regulatory pathway.

Authors:  Xuejun Jiang; Hyun-Eui Kim; Hongjun Shu; Yingming Zhao; Haichao Zhang; James Kofron; Jennifer Donnelly; Dave Burns; Shi-Chung Ng; Saul Rosenberg; Xiaodong Wang
Journal:  Science       Date:  2003-01-10       Impact factor: 47.728

10.  Apoptosis-related fragmentation, translocation, and properties of human prothymosin alpha.

Authors:  Alexandra G Evstafieva; George A Belov; Yuri P Rubtsov; Markus Kalkum; Bertrand Joseph; Nina V Chichkova; Elena A Sukhacheva; Alexey A Bogdanov; Ralf F Pettersson; Vadim I Agol; Andrey B Vartapetian
Journal:  Exp Cell Res       Date:  2003-04-01       Impact factor: 3.905

View more
  4 in total

1.  Loss of nuclear prothymosin-α expression is associated with disease progression in human superficial bladder cancer.

Authors:  Yuh-Shyan Tsai; Yeong-Chin Jou; Chun-Liang Tung; Chang-Te Lin; Cheng-Huang Shen; Syue-Yi Chen; Hsin-Tzu Tsai; Chen-Li Lai; Chao-Liang Wu; Tzong-Shin Tzai
Journal:  Virchows Arch       Date:  2014-04-15       Impact factor: 4.064

2.  Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential.

Authors:  Chrysoula-Evangelia Karachaliou; Ioannis V Kostopoulos; Vyronia Vassilakopoulou; Persefoni Klimentzou; Maria Paravatou-Petsotas; Wolfgang Voelter; Hubert Kalbacher; Christos Zikos; Ourania Tsitsilonis; Evangelia Livaniou
Journal:  Heliyon       Date:  2019-11-01

3.  Subcellular dissemination of prothymosin alpha at normal physiology: immunohistochemical vis-a-vis western blotting perspective.

Authors:  Caroline Mwendwa Kijogi; Christopher Khayeka-Wandabwa; Keita Sasaki; Yoshimasa Tanaka; Hiroshi Kurosu; Hayato Matsunaga; Hiroshi Ueda
Journal:  BMC Physiol       Date:  2016-03-01

Review 4.  Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications?

Authors:  P Samara; K Ioannou; O E Tsitsilonis
Journal:  Vitam Horm       Date:  2016-05-27       Impact factor: 3.421

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.